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Dare therapy continues to be an important components in the
tomes of patients after an acute myocardial infarction
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Reperf)teion therapy . particularly otraveem use ofthrom-
bolyhc drugs . is believed to be the most important ndranas
of the 1918s in the care of thane patients (I
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between 25% and 33% of patients with acute myocardial
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therapy (3-71. physician surveys and sales data suggest that
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agates (11,12). Despite these concerns, detailed current
intimatiod about usage patlsnn for these drugs is unavail.
able
. In particular, we know little about the impact of recent,
large, multicenter clinical trials (Second Gruppo Italian per
to Studio Della Sapravvivetaa ne8'httarto Macardico and
Third Inton ational Study of Infarct Survival), which com-
pared the beadtls and risks of ditrent thrombotytic agents
an the actual use of those agents.
To obtain a better undeestteufins of factors associated
with the me of t`-nmbolytic and other drug therapy, we
enamsecd patterns of care for all patients with acute myo-
cardial infarctia hospitalized at a diverse group of 88
hospitals in this country between 1988 and 1992.ODi goals
were I) to look at trends in usage overall as well as in usage
of specific agents during the most recent 5-year period and
2) to determine how use of these drugs varied with patient
and hospital characteristics .
Methods
Data ioon$. SMS Corporation. We analyzed patient-
level data from on-line administrative data bases maintained
by SMS Corporation, a nationwide supplier of health care
intimation and billing systems. The SMS data base is can-
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Wgore 3
. Use of calcium channel blockars
ICCBI and beta-blockers (BBL) in mic myo-
cardid in retina (AMI I patients, October 1987
to September 1992, On the erdlaate appears
the proportion of AMI patiens treated with
calcium
channel blockers and b.twblackens.
On the umism is the 5-s=e Period marked by
9snrler-yearn.
the preceding section. Specifically, after controlling for
patient age. roc, , smaller, payer and comorbiditics (including
congestive heart failure . diabetes
. hypertension and chronic
ischemic heart disease), and hospital bed size . teaching
status, proportion of patients eligible for Medicare, catheter-
ization ftcilities, ownership and location, thrombolytic use
was still lower in women than in men (adds ratio = 0 .84; 95`F
confidence interval, 0.79 to 0.90) and in blacks than in
o6Rblacks (odds ratio. 0.61 ; 95% confidence interval . 0.51 to
0.711. Patients whose care was reimbursed by Medicaid
underwent thrumbolysis less B •e
gnendy than those with
private insurance (odds ratio
: 0.74 ; 95% confidence interval .
(1.631o0 .86).
The logistic model also indicated hospital-level character-
issies that predicted tlwootbolysis use (not shown in tables)
.
For example
. patients in metropolitan hospitals were more
likely to receive thrombolysis (adds ratio = 1 .26; 95%
confidence ratio, 1 .17 to 135) than were patients in rural
hospitals. In 1988 and t%9, patients in hospitals with carh-
eterization facilities received thromholysis at higher rates
than those in hospitals without calheteriralien facilities .
However, the difference decreased over time, so that by
1990 there was no significant difference in The usage rates of
hospitals with or without a catheteization facility .
Use or other emdlac drugs, Between fiscal year 1988 and
fiscal year 1992, the use of calcium channel blacker% during
hospitalization for acute myocardial infection decreased
from 63% to 47% of patients. whereas the use of beta-
blockers during hospitalization for acute myocardial infarc-
tion increased from 29% to 38% (Fig . 31 . Age differences
noted above for thrombolysis also persisted for use of
beta-blockers
; however, gender and racial di&Fcaus were
not as clinically striking (Fig . 4). For example, alter adjust-
ing for age and race, the odds ratio For women relative to
men for receiving beta-backers was 0
.93 (95% confidence
PASHO 'tT AL .
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interval
. 0 .90 to 0
.96) and for calcium channel blackens 1 .09
(1
.06. 1 .13). Also. after adjusting for age and gender, the
odds ratio for blacks relative to nonblacks for receiving
beta-blockers was 0.81 (95ff confidence interval . 0 .76 to
0 .561 and calcium channel blockers 1 .03 (0.97 to 1
.09). As
with throlnbolysis, these relations persisted when we con-
trolled for clinical characteristics- including the existence of
congestive heat fhilure, diabetes . hypertension. chronic
ischcmic heart disease and other comerbidities.
Discsasalon
This study was designed to provide insights into the use
of thrombulytic agents and other cardiac drugs in a large
melonal sample of patients hospitalized for an acute myo-
cadinl inf nctiou
. Although hospitals in this study are not
proportionally representative of the nation's acute care hos-
pitals, their elderly Medicare patients are (Table 3)
.
Our fhrd(ngs suggest that the use of thrombolytic therapy
tutween fiscal year 1990 and fiscal year 1992 was low (about
18%%)
; this rate is somewhat higher than the 10% estimated
by some (7) but lower than the proportion of the population
thought to benefit from thrombolysis (25% to 33%) (3-5,7) .
Moreover, because the hospitals in this sample are weighted
somewhat toward larger . metropolitan and teaching institu-
tions (types of facilities thought to be more aggressive in
terms of new therapies), our estimates may be even higher
than the actual rates across all acute-care institutions . Be-
cause these data reflect use of thrombolysis through Septem-
ber 1992. current practice patterns do not seem to
be
incorporating the use of thrombolyric therapy to the extent
most cardiologists believe appropriate .
Although tissue plasmi usgen activator is still the domi-
nant thrombolytic agent
. its use has declined considerably in
the Iasi 2 years
. This reduction seems to be related to the
Iirmesyra
Sara
Weukd,
muasmea
Saes NseNNh
asaara
presentation and publication of results from two major,
multicenter clinical trials that compared the use of streptoki.
ease with tissue plmminogen activator and other Ihrornbo .
lyric agents. Specifically, the use of tissue plaamilmgen
activator decreased and the use of atreptokimMe increased
after I) the publication of results of the Second Gruppo
Italian per to Studio Delta Sopravvivenza ne0'Infarto Mio .
cardico (16) in July 1990 showing that tissue plasminogen
activator and streptokinase were "equally effective and
safe", and 2) presentation and publication of "her results
of the Third International Study of Infarct Survival results at
the American College of Cardiology Scientific Conference in
March 1991 and in Lancet (17) in March 1992 . The presen-
tation at
the American College of Cardiology conference,
which received much media coverage, led to the largest drop
in usage (Fig. 1) . This result suggests that dissemination of
the results o clinieai trials elects practice patterns in
hospitals at Imp, not just in hospitals participating in trials
as shown by Laws and colleagues
(18) . This conclusion con
be tested by reviewing the use of the two main thrombolytic
agents before and after the dissemination in 1993 of the
results of the Global Utilization of Streptokinase versus
Tissue Plasminogen Activator Occlusion (GUSTO) trial (19).
Of course, the two previous trials did not resolve all the
controversies about the relative benefits and risks tithe two
thrombolytio agents, nor did the trials establish the clear
superiority done agent over the other. Although we believe
that our findings show that the results
of
clinical trials arc
important to cardioogistta, we acknowledge that there are
other factors that physicians consider with respect to their
choice of therapy . Furthermore, drug therapies may be
administered by other than cardiologists, who may interpret
the clinical literature differently (to).
It is perhaps not Surprising that thrombolysis
is used loss
frequently in older patients (Fig . 2) because randmoined
clinical trials of thrombolysis have leaded to exclude pa .
tients over 70 or 75 years, so the clinical basis for its use is
JAGCVol.23 .N,S
April 19941013d0
Flew 4. Use of thrcmbulysis, calcium
chanced Mockers and beta-Makers by gen-
der and nee, focal year 1992. On the ar&
mode appeals the psupertian of scam myo-
cardial
infarction (AMU patients treated
with llosmddysis, calcium cheasd block-
as ad heta-bkckers.
On
ore abscissa are
the usage rams for blacks and noublach of
each gender.
not
well established In the very elderly (5,7,8,20,21) . Al-
though a comensus does not exist about the benefits of
thrombolysis in patients over 75. Krumholz and colleagues
(22) have shown that thrombolysis is beneficial in the very
elderly, and the 11% usage rate found in the 75- to 79-year
age group in fiscal year 1992 (Fig . 2) suggests that many
physicians concur with this view. Moreover, the jump in
thrombdysis use in the older age groups between fatal year
1988 and fiscal year 1992 Suggests that physicians are be
.
condng more comfortable with using thrombolytic therapy in
elderly patients.
A review of the utilization rates or other cardiac drugs
also revealed interesting means. Forenample, despite wide
.
spread evidence of the value of bas-0lockcrs (11 .23,24).
Oversell only about 38% of patients in fiscal year 1992 (an
increase from 29% in fiscal year 1988) received them timing
their hospitalization for acute myocardial infarction . Mean-
while, the declining use of akium'channel blockers (from
63% in And yew 1988 to 47% In fad year 1992) illustrates
their falling
out
of favor far use in pmlems with acute
myocardial infarction (I1,23). These changes are most likely
related to results of studies published before this 5-year
period . For example. by September 1987. 50 sides of
beta-blockera (with 31A16 patkmd and 12 smdiea of eakium-
dTamnel blotters (with 5,879 patients) had ban published,
showing the benefits of the corner but not the latter (11).
Our data permits to the use of these drugs in the in-
hospital phase of treatment for acme myocardial infarction .
We cannot tell from these data which drugs patients were
receiving before admission to determine, forextmtple. if high
use of calcium channel blacken in hospital can be explained
w simply as a conmmation of high use before admission.
However, two other sources suggest that this reason is not
the can. 1.5rst, we round in a preliminary unpublished
review of detailed patient chart dam on another cohort of
elderly patients with acute myocardial infarction in mid 1990
that calcium channel blockers were used in <30% of the
1022
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patients before the infarction and in about 65% during
the hospitalization. Also, lamas and colleagues (18) found
in the SAVE clinical trial that 23% were taking them before
the infmctien and 425'5 received them during the hospiWliza-
tien.
The differences in cardiac drug use by gender parallel
previously reported differeu-ues in cardiac praedutal use for
patients with acme myocardial infarction (25
.6) and with
omoney artery disease (27) but may be more difficult to
explain (28). Our analysis shows that differences are trot
attributable to variation in measured comurbiditics . such as
diabetes, hypertension, congestive heart failure or chronic
ischemic heart disease. Because !he use of thrombolysis in
men is still below the estimated rate of the population
thought to benefit from thrambelysis . overuse (29) is not
likely to be the predominant explanation . Perhaps. delays in
admission by women with acute myocardial infarction rep
resents more likely explanation
(30). However, there are no
obvious reasons why women should be treated less often
with other therapies generally thought to be useful, such as
beta-blockers (odds ratio - 0
.93), or more often with cal-
cium channel blockers (odds ratio = 1
.09), which are thought
to be less useful. Further clinical research should examine
the possible role of gorier differences io clinical presents-
doe (for example, loss ST elevation in women), which an
stet captured in claim data bases such as ours .
Our dad also subatunibee racial differences in inpatient
cardiac drug use previously reported for cardiac procedure
use (31-34). Our analysis shows that differences ate not
attributable to variation in measured comorhidities . As with
gender. overuse in nuablacks probably does not fully explain
the racial diferences, and previous studies have found no
difference in time to hospital admission for acute myocardial
infarction between patients of different race 130). A nmnber
ofothrpotentialfhaors,ineludlng :lifferr
includintliftrerces in Severity of
illues. preferences far aggressive ere and him on the pan
of providers. have been discussed previousb in the context
of racial dlferenees in cardiac procedural use (32-34) and
may he similarly responsible here .
In terms of payer status, the differences in drug use by
payer again parallel previously reported differences in car-
diac procedure use for patients with coronary artery disease
(32,35) . That a paient's Medicaid status affects the patient's
usage rate of thrombolysis is a disturbing finding, It suggests
that physicians treat their patiats insured by Medicaid less
aggressively (In terms of thrmbolysis) than patients with
private insurance
. The reasons for this are unclear.
Use of the SMS data base provided a unique opportunity
to review the experiences of mare than 65,011 patients over
a 5-year period from td hospitals . Although data on drug
utilization can be obtained in a single institution by manually
reviewing medical records, these data are difficult to
obtain
hem multiple institutions because of the administrative
burden. Moreover, Medicare billing data for hospitalized
patients do not include information on the use of specific
1029
drugs
. The absence of studies such as ours is partly ex-
plained by the paucity of adequate drug data .
Several factors boost confidence in the reliability of these
data. First. she SMS data are routinely used by the hospitals
for a variety of hospital management purposes, such as
examination of practice patterns, utilization review, total
quality management and medical audits. In the course of
fulfilling these renpoosibilities
. the hospitals have periodi-
cally validated the SMS data with medical chart information
to ensure that they reflect actual patient care
. Additionally,
the portions of the SMS data on Medicate beneficiaries are
sent to fiscal intermediaries and become part of the L{e,iicare
claims data base that are now routinely used to examine the
process and outcomes of care. Second, because all hospitals
participating in this study need and use the SMS data to
obtain reimbursement, they lure an obvious incentive to
collect these data accurately and comprehensively, particu-
larly if the charges for one (tissue plasminogen activator) are
generally more than $2,000
. Third, data collection is based
an an
on-fine "order-entry" system. From this perspective,
if anything, our estimates could be overestimates because
the drugs might have been ordered but not administered .
Fourth. the SMS dam base has been successfully used in
other research projects examining use and costs of care .
mortality and patient characteristics (36-38)
. Fifth, our
sensitivity analysis detern iced that even if the SMS data did
underreport the usage rates of thrumbolysis by 15%, we
would still have concluded that the usage rates were lower
than expected
. Finally, the trends observed in Figure 1
consistent with the bW clinical trials would not likely have
been detected if data collection were inaccurate .
As it, many other siturtioes, more data would be useful .
The implications of or findings would be more apparent if
we had more comprehensive clinical data . Nevertheless,
because souse of the usage cater that we found are either
distressingly low or distressingly high, it is unlikely that they
would be changed in a nsajor way by mote detailed adjust-
ment Although she level of information an severity and
comorbidity in the available data may be insufficient to
assess the appropriateness of care at the patient level, the
overall pattern or fodimgs may provide useful insight for
quality improvement activities locally and nationally. Thus,
we believe that further study of current patterns of usage
should be a high priority . If our results can be replicated, a
major educational initiative should be undertaken to ensure
that the joint American College of Cardiology-American
Heart Association guidelines for the care of patients with an
acute myocardial infarction are followed .
We shunt Man Anon, MD.
Lm Gold . .
. MD and George trdboult, MD
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